Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. PT Royal Prima Tbk's EBITDA for the
three
months ended in Mar. 2026 was Rp-3,515 Mil. PT Royal Prima Tbk's Revenue for the
three
months ended in Mar. 2026 was Rp71,856 Mil. Therefore, PT Royal Prima Tbk's EBITDA margin for the quarter that ended in Mar. 2026 was -4.89%.
PT Royal Prima Tbk (ISX:PRIM) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
PT Royal Prima Tbk EBITDA Margin % Related Terms
PT Royal Prima Tbk EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for PT Royal Prima Tbk's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:PRIM vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, PT Royal Prima Tbk's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Royal Prima Tbk EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, PT Royal Prima Tbk's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where PT Royal Prima Tbk's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Royal Prima Tbk (ISX:PRIM) has a EBITDA Margin % of -4.89% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PT Royal Prima Tbk and its competitors. According to the industry distribution chart, PT Royal Prima Tbk ranks #528 out of 664 companies in the Healthcare Providers & Services industry, placing it in the top 79.5%.
Is PT Royal Prima Tbk's EBITDA Margin % too high?
PT Royal Prima Tbk's current EBITDA Margin % is -4.89%. Based on the distribution chart, PT Royal Prima Tbk ranks #528 out of 664 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, PT Royal Prima Tbk has a GF Score™ of 74/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PT Royal Prima Tbk's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, PT Royal Prima Tbk ranks #528 out of 664 companies for EBITDA Margin %. This places PT Royal Prima Tbk in the lower half of its industry. The industry median EBITDA Margin % is 10.24. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.24, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PT Royal Prima Tbk and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Royal Prima Tbk's current EBITDA Margin % is -4.89%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Royal Prima Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Royal Prima Tbk (ISX:PRIM) is currently considered Modestly Overvalued. The stock's GF Value™ is Rp81.59, compared to a current price of Rp98.00 — trading 20.1% above its estimated fair value. The current EBITDA Margin % is -4.89%. PT Royal Prima Tbk's overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For PT Royal Prima Tbk (ISX:PRIM), the current EBITDA Margin % is -4.89% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Royal Prima Tbk (ISX:PRIM) Overvalued in 2026?
Based on GuruFocus' analysis, PT Royal Prima Tbk stock appears to be overvalued.
The current stock price of Rp98.00 is trading 20.1% above its estimated GF Value™ of Rp81.59.
GuruFocus considers PT Royal Prima Tbk to be Modestly Overvalued.
Key valuation signals for ISX:PRIM:
EBITDA Margin %: -4.89%
GF Value™: Rp81.59 vs. price of Rp98.00 (20.1% above fair value)
No single metric tells the full story. See the ISX:PRIM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Royal Prima Tbk is engaged in health services which consist of the provision of hospital services, polyclinics, hall treatment, maternity hospital, and specialist hospital. It has three geographic segments: RSU Royal Prima, RS Royal Prima Jambi, and Rumah Sakit Marelan. The company generates the majority of its revenue from RSU Royal Prima segment. The company generates revenue from Drugs and medical supplies, doctors' and nurses' fees, Hospital facilities, Room services, and Others.
74GF Score
Get the complete analysis for ISX:PRIM
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:PRIM has been successfully added to your 
